Barclays analyst Gena Wang lowered the firm’s price target on Regenxbio (RGNX) to $37 from $50 and keeps an Overweight rating on the shares following the Q2 report.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RGNX:
- REGENXBIO Reports Q2 2025 Financial Results and Progress
- Regenxbio launches program for surabgene lomparvovec in diabetic retinopathy
- RegenXBio and AbbVie Amend Collaboration Agreement
- Regenxbio reports Q2 EPS ($1.38) vs. ($1.05) last year
- Regenxbio says cash position to fund operations into early 2027